Uptake of Fluorescein via a pH-Dependent Monocarboxylate Transporter by Human Kidney 2 (HK-2) Cells
Biol Pharm Bull. 2024;47(1):79-87. doi: 10.1248/bpb.b23-00570.ABSTRACTHerein, we investigated whether a fluorescent probe for an organic anion transporter (OAT), fluorescein (FLS), could be accumulated by human kidney 2 (HK-2) cells derived from human kidney proximal tubular epithelia. HK-2 cells took up FLS in a pH-dependent and concentration-dependent manner. FLS accumulation by HK-2 cells was inhibited by monocarboxylic acids, ibuprofen, rosuvastatin, and indoleacetic acid but not by typical substrates for OATs. A typical protonophore, carbonyl cyanide p-trichloromethoxyphenylhydrazone completely abolished FLS accumulat...
Source: Biological and Pharmaceutical Bulletin - January 3, 2024 Category: Drugs & Pharmacology Authors: Takaharu Takiguchi Kazuaki Sugio Masayuki Masuda Shotaro Sasaki Seiji Miyauchi Source Type: research
Uptake of Fluorescein via a pH-Dependent Monocarboxylate Transporter by Human Kidney 2 (HK-2) Cells
Biol Pharm Bull. 2024;47(1):79-87. doi: 10.1248/bpb.b23-00570.ABSTRACTHerein, we investigated whether a fluorescent probe for an organic anion transporter (OAT), fluorescein (FLS), could be accumulated by human kidney 2 (HK-2) cells derived from human kidney proximal tubular epithelia. HK-2 cells took up FLS in a pH-dependent and concentration-dependent manner. FLS accumulation by HK-2 cells was inhibited by monocarboxylic acids, ibuprofen, rosuvastatin, and indoleacetic acid but not by typical substrates for OATs. A typical protonophore, carbonyl cyanide p-trichloromethoxyphenylhydrazone completely abolished FLS accumulat...
Source: Biological and Pharmaceutical Bulletin - January 3, 2024 Category: Drugs & Pharmacology Authors: Takaharu Takiguchi Kazuaki Sugio Masayuki Masuda Shotaro Sasaki Seiji Miyauchi Source Type: research
Risk Factors Analysis of Severe Liver Injury Induced by
Statins
Horm Metab Res DOI: 10.1055/a-2210-3395The aim of this study is to report the risk factors of severe statin induced
liver injury (SILI). From the database of Shandong ADR Monitoring Center and
Outpatients and inpatients in our hospital, SILI cases reported from 2013 to
2021 were extracted and screened. The diagnostic criteria of SILI, the inclusion
and exclusion criteria of severe and general SILI were established separately.
After the SILI cases were selected and confirmed, the socio-demographic and
clinical characteristics were collected. Single factor chi-squar...
Source: Hormone and Metabolic Research - January 3, 2024 Category: Endocrinology Authors: Su, Feng-yun Li, Wen-hua Zhao, Xu-dong Han, Qian Xu, Xin Geng, Tao Tags: Original Article: Endocrine Care Source Type: research
Incidence Of Adverse Events Is Higher When Heart Transplant Recipients Are On High Versus Standard Dose Statin In Combination With Cyclosporine
Heart transplant recipients receive a calcineurin inhibitor (CNI) for immunosuppression. While tacrolimus is the CNI of choice, switching to cyclosporine (CSA) may be necessary due to side effects. Treatment with a statin decreases incidence of cardiac allograft vasculopathy and mortality post-transplant. CSA interacts with statins by increasing their levels, with high intensity statins often contraindicated. Per the AHA, maximum recommended statin doses for heart transplants on CSA include atorvastatin 10 mg, pravastatin 20 mg, rosuvastatin 5 mg, and fluvastatin 40 mg. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Gabriel E. Diaz, Besher Kashlan, Cole Block, Jenna Negrelli, Michelle Fine, Joshua Newman, Mingxi D. Yu, Max Liebo Tags: 153 Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review
CONCLUSION: This meta-analysis showed that 5 mg rosuvastatin/10 mg ezetimibe had largely comparable lipid-modifying efficacy and tolerability as 20 mg rosuvastatin.PMID:38154476 | PMC:PMC10774651 | DOI:10.3349/ymj.2023.0285 (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - December 28, 2023 Category: Universities & Medical Training Authors: Yura Kang Jung Mi Park Sang-Hak Lee Source Type: research
Influence of the rs4238001 Genetic Polymorphism of the SR-B1 Gene on Serum Lipid Levels and Response to Rosuvastatin in Myocardial Infarction Iraqi Patients
Biochem Genet. 2023 Dec 22. doi: 10.1007/s10528-023-10613-4. Online ahead of print.ABSTRACTScavenger receptor type B (SR-BI) is a receptor that binds both native and altered lipoproteins. It was revealed to facilitate utilization of high-density lipoprotein HDL and significantly affect the reverse transport of cholesterol. Therefore, the objectives were to identify the possible role of the genetic variant rs4238001 in patients with myocardial infarction (MI) on serum lipid level, and how this variant could impact the response of rosuvastatin drug. The genotyping of the rs4238001 genetic polymorphism of the SR-B1 gene was p...
Source: Biochemical Genetics - December 22, 2023 Category: Genetics & Stem Cells Authors: Shaimaa Y Abdulfattah Huda Salman Alagely Farah T Samawi Source Type: research
